Tiziana Life Sciences PLC Sponsored ADR Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, Universi...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a pro...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Sto...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5 million raised through the sale of 5,263,158 common shares at $0.95 each, with closing expected around November 1, 2024, The agreement also includes an option allowing the investor to acquire an a...

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million